Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. Theranostics Market Insights
3.1. Theranostics – Industry snapshot
3.2. Theranostics - Ecosystem analysis
3.3. Theranostics Market dynamics
3.3.1. Theranostics – Market Forces
3.3.1.1. Theranostics Market driver analysis
3.3.1.2. Theranostics Market restraint/challenges analysis
3.3.1.3. Theranostics Market opportunity analysis
3.4. Industry analysis - Porter's five force
3.4.1. Bargaining power of supplier
3.4.2. Bargaining power of buyer
3.4.3. Threat of substitute
3.4.4. Threat of new entrant
3.4.5. Degree of competition
3.5. Theranostics Market PEST analysis, 2017
3.5.1. Theranostics Industry trends
3.5.2. Competitive Ranking Analysis
4. Theranostics Market Size and Forecast by Disease Type
4.1. Key findings
4.2. Neurological Disorders
4.2.1. Global market estimates and forecasts, 2017 – 2026
4.3. Cardiovascular Diseases
4.3.1. Global market estimates and forecasts, 2017 – 2026
4.4. Oncology Disorders
4.4.1. Global market estimates and forecasts, 2017 – 2026
4.5. Immunological Disorders
4.5.1. Global market estimates and forecasts, 2017 – 2026
5. Theranostics Market Size and Forecast by Technology
5.1. Key findings
5.2. Polymerase Chain Reaction (PCR)
5.2.1. Global market estimates and forecasts, 2017 - 2026
5.3. In-situ Hybridization
5.3.1. Global market estimates and forecasts, 2017 – 2026
5.4. Immunohistochemistry
5.4.1. Global market estimates and forecasts, 2017 – 2026
5.5. Sequencing
5.5.1. Global market estimates and forecasts, 2017 – 2026
6. Theranostics Market Size and Forecast by Regions
6.1. Key findings
6.2. North America
6.2.1. Theranostics Market by Disease Type, 2017 - 2026
6.2.2. Theranostics Market by Technology, 2017 - 2026
6.2.3. U.S.
6.2.3.1. Theranostics Market by Disease Type, 2017 - 2026
6.2.3.2. Theranostics Market by Technology, 2017 - 2026
6.2.4. Canada
6.2.4.1. Theranostics Market by Disease Type, 2017 - 2026
6.2.4.2. Theranostics Market by Technology, 2017 - 2026
6.3. Europe
6.3.1. Theranostics Market by Disease Type, 2017 - 2026
6.3.2. Theranostics Market by Technology, 2017 - 2026
6.3.3. Germany
6.3.3.1. Theranostics Market by Disease Type, 2017 - 2026
6.3.3.2. Theranostics Market by Technology, 2017 - 2026
6.3.4. UK
6.3.4.1. Theranostics Market by Disease Type, 2017 - 2026
6.3.4.2. Theranostics Market by Technology, 2017 - 2026
6.3.5. France
6.3.5.1. Theranostics Market by Disease Type, 2017 - 2026
6.3.5.2. Theranostics Market by Technology, 2017 - 2026
6.3.6. Italy
6.3.6.1. Theranostics Market by Disease Type, 2017 - 2026
6.3.6.2. Theranostics Market by Technology, 2017 - 2026
6.4. Asia Pacific
6.4.1. Theranostics Market by Disease Type, 2017 - 2026
6.4.2. Theranostics Market by Technology, 2017 - 2026
6.4.3. China
6.4.3.1. Theranostics Market by Disease Type, 2017 - 2026
6.4.3.2. Theranostics Market by Technology, 2017 - 2026
6.4.4. India
6.4.4.1. Theranostics Market by Disease Type, 2017 - 2026
6.4.4.2. Theranostics Market by Technology, 2017 - 2026
6.4.5. Japan
6.4.5.1. Theranostics Market by Disease Type, 2017 - 2026
6.4.5.2. Theranostics Market by Technology, 2017 - 2026
6.4.6. Australia
6.4.6.1. Theranostics Market by Disease Type, 2017 - 2026
6.4.6.2. Theranostics Market by Technology, 2017 - 2026
6.5. Latin America
6.5.1. Theranostics Market by Disease Type, 2017 - 2026
6.5.2. Theranostics Market by Technology, 2017 - 2026
6.5.3. Brazil
6.5.3.1. Theranostics Market by Disease Type, 2017 - 2026
6.5.3.2. Theranostics Market by Technology, 2017 - 2026
6.5.4. Mexico
6.5.4.1. Theranostics Market by Disease Type, 2017 - 2026
6.5.4.2. Theranostics Market by Technology, 2017 - 2026
6.6. Middle East & Africa
6.6.1. Theranostics Market by Disease Type, 2017 - 2026
6.6.2. Theranostics Market by Technology, 2017 - 2026
7. Company Profiles
7.1. F Hoffman La Roche
7.1.1. Overview
7.1.2. Financials
7.1.3. Product Benchmarking
7.1.4. Recent Developments
7.2. Thermo Fisher Scientific Inc.
7.2.1. Overview
7.2.2. Financials
7.2.3. Product Benchmarking
7.2.4. Recent Developments
7.3. GE Healthcare
7.3.1. Overview
7.3.2. Financials
7.3.3. Product Benchmarking
7.3.4. Recent Developments
7.4. Agilent Technologies
7.4.1. Overview
7.4.2. Financials
7.4.3. Product Benchmarking
7.4.4. Recent Developments
7.5. Qiagen NV
7.5.1. Overview
7.5.2. Financials
7.5.3. Product Benchmarking
7.5.4. Recent Developments
7.6. Foundation Medicine
7.6.1. Overview
7.6.2. Financials
7.6.3. Product Benchmarking
7.6.4. Recent Developments
7.7. Leica Biosystems Nussloch GmBH
7.7.1. Overview
7.7.2. Financials
7.7.3. Product Benchmarking
7.8. Pfizer, Inc.
7.8.1. Overview
7.8.2. Financials
7.8.3. Product Benchmarking
7.8.4. Recent Developments